Codexis ((CDXS)) has held its Q4 earnings call. Read on for the main highlights of the call.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Codexis struck a cautiously optimistic tone on its latest earnings call, spotlighting sharp revenue growth, stronger margins, and a bolstered cash position while acknowledging that its ECOsynthesis platform is still early-stage and service-heavy. Management emphasized technical and commercial milestones that de‑risk the story, but stressed execution and timing risks as the company remains loss‑making.
Revenue Rebound and Margin Strength
Codexis posted quarterly revenue of $38.9 million, up about 81% year over year from $21.5 million, with full-year revenue climbing 19% to $70.4 million. Product gross margin improved meaningfully to 64% in 2025 from 56% a year earlier, and management expects these healthier margin levels to hold roughly steady into 2026.
Merck Deal Delivers Non-Dilutive Capital
A technology transfer agreement with Merck contributed roughly $37.8 million in non-dilutive capital in the fourth quarter of 2025, providing an important liquidity boost without issuing new equity. This one-time inflow significantly padded the balance sheet and underpinned the stronger bottom-line performance seen in the most recent quarter.
Cash Runway Extends Through 2027
The company closed 2025 with $78.2 million in cash, cash equivalents, and short-term investments, giving management confidence it can fund operations and planned capital spending through 2027. This runway is particularly important as Codexis invests heavily in ECOsynthesis scale-up and GMP infrastructure while it works to convert its growing pipeline into durable revenue.
ECOsynthesis Scale-Up Hits Key Technical Marks
On the technology front, Codexis delivered 10 grams of commercially relevant siRNA using fully sequential ECOsynthesis and is now operating at 100-gram scale in its Eco Innovation Lab. The company is targeting roughly 0.5 kilogram scale by the end of 2026, while a client has already used Codexis ligase to manufacture a 3 kilogram siRNA batch via chemoenzymatic methods.
Commercial Traction and CDMO Partnerships
Commercial engagement around ECOsynthesis appears to be gaining momentum, with three CDMO agreements signed in 2025 with Bachem, Nitto Avecia, and Axolabs. Codexis also secured a low seven-figure contract from an emerging biotech to supply 50 grams of fully enzymatic siRNA, and now counts 55 opportunities across 40 companies in its sales pipeline.
Quality Upgrades and GMP Infrastructure Build-Out
The company modernized its non-GMP production capabilities in Redwood City, achieved ISO 9001 certification, and successfully passed a facility and quality inspection by a major pharmaceutical client. Codexis also leased a GMP plant in 2025 and plans to begin retrofit construction in the second half of 2026, with the site expected to be fully operational by the end of 2027.
Net Loss Narrows and Profit Metrics Improve
Operating performance showed clear progress, with full-year net loss shrinking to $44.0 million from $65.3 million, a reduction of roughly one-third. Notably, the fourth quarter flipped to a positive net income of $9.6 million versus a $10.4 million loss in the year-ago period, reflecting higher revenue, better margins, and the Merck contribution.
Persistent Annual Losses and Cash Burn
Despite quarterly profitability, Codexis remains unprofitable on a full-year basis, with the $44.0 million net loss underscoring ongoing cash burn. Management acknowledged that continued investment in ECOsynthesis, along with the coming GMP facility build-out, will keep pressure on the P&L and necessitates disciplined cost and capital management.
ECOsynthesis Still Early and Service-Weighted
Management highlighted that current ECOsynthesis revenue is dominated by feasibility work and service contracts, which offer limited margin contribution at this stage. The long-term economic upside depends on converting today’s evaluations into higher-margin, multi-year licensing, clinical supply, and commercial supply deals, a transition that carries timing and execution risk.
Guidance Points to Modest Growth, H2 Skew
Codexis guided 2026 revenue to a range of $72 million to $76 million, implying only modest growth from 2025’s $70.4 million base and a revenue profile skewed toward the second half of the year. The company expects product gross margins to hold near 64% and projects combined operating expenses and capital expenditures to be broadly similar to 2025 levels after restructuring-driven savings.
R&D Investment and GMP Build Raise Spend
Full-year R&D spending increased to $52.3 million from $46.3 million, reflecting higher staffing and lab costs tied to ECOsynthesis development and scale. The fourth quarter also included a $3.4 million restructuring charge, and upcoming capital expenditures to retrofit the GMP facility will add to cash needs even as management leans on its extended runway.
Reliance on Partner Deals and Milestones
The recent revenue surge was heavily influenced by the Merck technology transfer, underscoring Codexis’s dependence on major partnerships and milestone events. Looking ahead, the company’s growth case hinges on turning feasibility and CDMO assessments into recurring licensing, referral revenue-sharing, and commercial supply agreements, outcomes whose size and timing remain uncertain.
New Features Await Clinical and Commercial Proof
Codexis touted promising technical advances such as stereochemical control within ECOsynthesis, positioning them as potential differentiators for oligonucleotide customers. However, meaningful value creation will depend on preclinical and clinical validation and broader customer adoption, with management planning additional data disclosures in 2026 but acknowledging that commercial impact is still unproven.
Forward Guidance and 2026 Operational Goals
Looking ahead, Codexis aims to scale ECOsynthesis from its current 100-gram operations toward roughly 0.5 kilogram by late 2026 while starting GMP plant retrofit construction in the second half of the year. The company targets at least one additional licensing deal and plans to advance its 55-opportunity pipeline, all while maintaining stable gross margins and managing spending against its cash runway through 2027.
Codexis’s latest earnings call portrayed a company making tangible strides in technology, partnerships, and financial discipline, yet still navigating an early commercial phase with meaningful risk. For investors, the story now hinges on whether ECOsynthesis can transition from service-heavy feasibility work to scalable, higher-margin product and licensing revenue over the next few years.